



# Source details

## Urological Science

Open Access ⓘ

Scopus coverage years: from 2010 to 2022

Publisher: Wolters Kluwer Health

ISSN: 1879-5226 E-ISSN: 1879-5234

Subject area: Medicine: Urology

Source type: Journal

CiteScore 2021

0.7



SJR 2021

0.158



SNIP 2021

0.356



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology



CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▼

$$0.7 = \frac{112 \text{ Citations 2018 - 2021}}{172 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$0.8 = \frac{123 \text{ Citations to date}}{155 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

### CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
Urology	#77/99	22nd

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

---

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.







Protect Your Devices Today  
McAfee Official Store

## Urological Science

### COUNTRY

Netherlands

-  Universities and research institutions in Netherlands
-  Media Ranking in Netherlands

### SUBJECT AREA AND CATEGORY

Medicine  
Urology

AJE's Free Grammar Check Tool 



Open 

### PUBLISHER

Wolters Kluwer Medknow Publications

### H-INDEX

9

### PUBLICATION TYPE

Journals

### ISSN

18795226, 18795234

### COVERAGE

2010-2021

### INFORMATION

- [Homepage](#)
- [How to publish in this journal](#)
- [urological.science@tua.org.tw](mailto:urological.science@tua.org.tw)


AJE's Free Grammar Check Tool 





Open 

### SCOPE

Urological Science is a multispecialty journal of urology and invites manuscripts from researchers in the different fields of urology. Urological Science serves as a platform for researchers in basic and clinical urology in the East and South-East Asia. Readers and researchers all around the world are welcome too. The journal provides up-to-date information related to daily practice of urology, particularly those with regional differences in East and South-East Asia.

 Join the conversation about this journal








AJE's Free Grammar Check Tool 

AJE 

FIND SIMILAR JOURNALS ?

options

<p>1 <b>BMC Urology</b> GBR</p> <p><b>93%</b> similarity</p>	<p>2 <b>Research and Reports in Urology</b> NZL</p> <p><b>91%</b> similarity</p>	<p>3 <b>Current Urology</b> USA</p> <p><b>90%</b> similarity</p>	<p>4 <b>Turkish Journal of Urology</b> TUR</p> <p><b>90%</b> similarity</p>	<p>5 <b>Archivio Italiano di Urologia Andrologia</b> ITA</p> <p><b>88%</b> similarity</p>
--	--	--	---	---



**Urological Science**

← Show this widget in your own website

Urology

Q4

best quartile

SJR 2021

0.16

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" >
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our **new data visualization tool**.



Loading comments...

Developed by:



Powered by:



Follow us on [@ScimagoJR](#)

Scimago Lab, Copyright 2007-2022. Data Source: [Scopus®](#)

EST MODUS IN REBUS  
Horatio (Satira 1,1,106)

[Cookie settings](#)

[Cookie policy](#)

ISSN 1673-5397 (print)  
ISSN 1673-5398 (online)

# Urological Science

www.e-urosci.com

Volume 35  
Issue 2  
September-October 2018

Guest Editor: Lukman Hakim



Regenerative endoprostatectomy for advanced prostate cancer



Taiwan Urological Association



Medknow Group | Medknow



## Table of Contents

[Next Issue](#)

[Previous Issue](#)



**September-October 2019**

Volume 30 | Issue 5

Page Nos. 197-242

Online since Thursday, October 24, 2019

Accessed 32,645 times.

### PDF access policy

Journal allows immediate open access to content in HTML + PDF

[View issue as eBook](#)

[Issue citations](#)

[Issue statistics](#)

[RSS](#)

[SUBMIT ARTICLE](#)

[POPULAR ARTICLES](#)

[JOIN AS REVIEWER](#)

[GET EMAIL ALERTS](#)


[RECOMMEND](#)

[Show all abstracts](#) [Show selected abstracts](#) [Export selected to](#) [Add to my list](#)


### EDITORIALS

- Adiponectin and proto-oncogene MYC in prostate cancer: How far are we with the evidence?** p. 197  
Lukman Hakim  
DOI:10.4103/UROS.UROS\_69\_19  
[\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)
- Urological science going south** p. 199  
Stephen Shei-Dei Yang  
DOI:10.4103/UROS.UROS\_74\_19  
[\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)


### REVIEW ARTICLE

- Randall's plaque, the origin of nephrolithiasis: Where do we stand now?** p. 200  
 Li-Hsien Tsai, Chao-Hsiang Chang, Szju-Ju Chen, Wen-Chi Chen  
DOI:10.4103/UROS.UROS\_144\_18  
[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(5\)\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)

### ORIGINAL ARTICLES : BASIC SCIENCE

- Histopathological analysis and scanning electron microscopic study of chlorpyrifos exposed kidney of neonates in pregnant rats exposed during gestation period** p. 206  
 Jyoti Upadhyay, Nidhi Tiwari, Mahendra Rana, Satpal S Bisht  
DOI:10.4103/UROS.UROS\_27\_19  
[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)

### ORIGINAL ARTICLES: CLINICAL SCIENCE


- Characteristics of bacterial colonization after indwelling ureteral stents in urinary stone patients with diabetes mellitus and chronic kidney disease** p. 211  
Anak Agung Gede Oka, Gede Wirya Kusuma Duarsa, Sri Rahayu Wulandari, Tjokorda Gde Bagus Mahadewa, Budi Santosa, Wayan Yudianta, Pande Wisnu Tirtayasa  
DOI:10.4103/UROS.UROS\_124\_18  
[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)
- The effect of dutasteride and tomato extract combination on reducing blood loss after transurethral resection of the prostate** p. 216  
Eriawan Agung Nugroho, Selly Adyta Kemara, Siti Amarwati, Tommy Supit  
DOI:10.4103/UROS.UROS\_152\_18  
[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)
- The role of c-myc and adiponectin receptors in prostate cancer metastases** p. 220  
 Ferry Safriadi, Sugandi Sugandi, Rainy Umbas, Bethy Suryawati Hernowo  
DOI:10.4103/UROS.UROS\_153\_18  
[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]<sup>Beta</sup>](#)
- Presence of residual stones is not a contraindication for tubeless percutaneous nephrolithotomy** p. 226



Shun-Kai Chang, Chang-Te Lin, Chun-Hsiung Kang, Ming-Chin Cheng, Yeong-Chin Jou, Cheng-Huang Shen, Pi-Che Chen, Wei-Hong Lai

DOI:10.4103/UROS.UROS\_137\_18

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>




**Augmentation enterocystoplasty for patients with ketamine-induced cystitis: An 8-year experience and a review of series** p. 232

Chu-Hsuan Hung, Shu-Wei Hsieh, Shao-Kuan Chen, Chih-Ming Lin

DOI:10.4103/UROS.UROS\_46\_18

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>

**CASE REPORT**



**Thyrotoxic goiter and asymptomatic thyroid nodule as an initial presentation of clear cell renal cell carcinoma: A report of two cases** p. 238

Mohd Ghani Khairul-Asri, Simran Sidhu, Navarasi S Raja Gopal, Saiful Azli, Mohamed Abdelwahab Badawi, S.H.M Hadi, Omar Fahmy

DOI:10.4103/UROS.UROS\_141\_18

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>

**CME TEST**




**CME Test**

p. 241

DOI:10.4103/1879-5226.269891



[\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)<sup>Beta</sup>







## Editorial Board

[About the journal](#)

### Publishing Supervisor

Jacob See-Tong Pang, M.D.

Vice-Superintendent,

Chang Gung Memorial Hospital (CGMH), Linkou, Taoyuan, Taiwan

### Editors-in-Chief

Yao-Chi Chuang, M.D.

Professor,

Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

### Associate Editors

Jeff S. Chueh, M.D., Ph.D.

Professor & Chairman

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan

William J. Huang, M.D., Ph.D.

Professor, Director,

Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan

Shu-Pin Huang, M.D.

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Chun-Hou Liao, M.D., Ph.D.

Professor, Associate Dean,

College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

### Section Editors

Shang-Jen Chang, M.D. (Pediatrics)

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan

Chung-Hsin Chen, M.D., Ph.D. (Oncology)

Associate Professor,

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan

Shiu-Dong Chung, M.D., Ph.D. (Urolithiasis)

Associate Professor, Chief,

Department of Urology, Far Eastern Memorial Hospital, New Taipei City, Taiwan

Yung-Shun Juan, M.D., Ph.D. (Functional Urology)

Professor, Chief,

Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

[SUBMIT ARTICLE](#)

[POPULAR ARTICLES](#)

[JOIN AS REVIEWER](#)

[GET EMAIL ALERTS](#)

[RECOMMEND](#)

Yung-Ming Lin, M.D. (Andrology)

Professor, Distinguished Expert,

Department of Urology, National Cheng Kung University & Hospital, Tainan, Taiwan

En Meng, M.D., Ph.D. (Female Urology)

Chief,

Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Yen-Chuan Ou, M.D., Ph.D. (Robotic Surgery)

Dean of Research & Development and Innovation Center, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan

Yao-Chou Tsai, M.D., Ph.D. (Laparoscopic Surgery)

Department of Medicine & Division of Urology, Taipei Tzu Chi Hospital, Taipei, Taiwan

Yuh-Shyan Tsai, M.D., Ph.D. (Oncology)

Professor,

Dept of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Ke-Hung Tsui, M.D. (BPH and prostatic Disease)

Professor,

Department of Medicine & Urology, Taipei Medical University-Shuang-Ho hospital, New Taipei City, Taiwan

#### **Editors**

Yu Chen, M.D.

Assistant Professor, Chief,

Division of Andrology and Female Urology, Department of Urology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

Eric Chieh-Lung Chou, M.D., Ph.D.

Professor,

Department of Urology, China Medical University Hospital, Taichung, Taiwan

Hsiao-Jen Chung, M.D.

Chief,

Division of General Urology, Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan

Chao-Yuan Huang, M.D., Ph.D.

Associate Professor,

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan

Yun-Ching Huang, Ph.D.

Chief,

Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan

Chi-Ping Huang, M.D., Ph.D.

Chief,

Department of Urology, China Medical University Hospital, Taichung, Taiwan

Hsiang-Ying Lee, Ph.D.

Associate Professor,

Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Jian-Ri Li, M.D., Ph.D.

Associate Professor, Director,

Division of Surgical Intensive Care Unit, Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan

Victor Chia-Hsiang Lin, M.D., Ph.D.

Professor, Director,

Division of Urology, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan

Chung-Cheng Wang, M.D., Ph.D.

Chief,

Department of Urology, En Chu Kong Hospital, New Taipei City, Taiwan.

Kai-Jie Yu, M.D.

Dr,

Director of Uro-Oncology section, Urology department, Surgery Division, Chang-Gung Memorial Hospital in Linkou, Taoyuan, Taiwan.

#### **International Editors**

Michael B. Chancellor, M.D.

Professor,

Department of Urology, Beaumont Health System, Royal Oak, MI, USA

Lukman Hakim

Doctor,

Department of Urology, Airlangga University Hospitals, Indonesia

Marie Carmela Lapitan

Professor,

Department of Surgery, Philippine General Hospital, University of the Philippines - Manila, Manila, Philippines

Teng Aik Ong

Associate Professor,

Department of Surgery, Faculty of Medicine, University of Malaya, Malaysia

Philippe E. Zimmern

Professor,

Department of Urology University of Texas Southwestern Medical Center, USA

Ganesan Adaikan

Professor,

Department of Obstetrics & Gynaecology, National University of Singapore

Tai Young Ahn

Professor,

Asian Medical Center and College of Medicine, University of Ulsan, Seoul, Korea

Edmund Chiong

Professor,

Department of Urology, National University Hospital, National University Health System, Singapore

John Krieger

Professor,

Department of Urology, University of Washington, Seattle, USA

Robert M. Levin

Professor,

Albany College of Pharmacy and Health Sciences, USA

Bannakij Lojanapiwat

Professor,

Division of Urology, Department of Surgery, Chiang Mai University, Thailand

Tom F. Lue

Professor,

Department of Urology, University of California (UCSF), San Francisco, San Francisco, USA

Tetsuro Matsumoto

Professor,

Department of Urology, University of Occupational and Environmental Health, Japan

Seiji Naito

Professor,

Graduate School of Medical Science Kyushu University, Japan

Quang Nguyen

Associate Professor,

Andrology and Urology, Center for Male Sexual Medicine, Viet Duc University Hospital, Hanoi, Vietnam

Osamu Ogawa

Professor,

Department of Urology, Kyoto University Graduate School of Medicine, Japan

Koon Ho Rha

Professor,

Department of Urology, Yonsei University, Seoul, Korea

Marshall Leedy Stoller

Professor,

University of California, San Francisco, USA

Hui Meng Tan

Professor,

Faculty of Medicine, University of Malaya and Sime Darby Medical Center, Subang Jaya, Selangor, Malaysia

Bin Tean Teh

Professor,

National Cancer Centre Singapore, Singapore

Robert E. Brannigan, M.D.

Professor,

Vice Chair of Clinical Urology, Department of Urology, Northwestern University, Feinberg School of Medicine, USA

**Managing Editors**

Yuan-Chi Shen, M.D.

Visiting Staff,

Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

I-Hung Shao, M.D.

Attending Physician, Assistant Professor,

Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, New Taipei City, Taiwan

Ming-Hsin Yang, M.D., Ph.D.

Division of Urology, Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan

Jui-Ming Liu, M.D., Ph.D.

Deputy Director,

Department of Medical Education and Research, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.

Attending Surgeon, Department of Urology, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.

**Statistical Consultants**

Teng-Kai Yang, B.S.

Department of Urology, Yonghe Cardinal Tien Hospital, New Taipei City, Taiwan

**Consultants**

Tai-Lung Cha, M.D.

Professor,

Division of Urology, Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan

Luke S. Chang, M.D.

Professor, Consultant,

Cheng Hsin Hospital, Taipei, Taiwan

Sun-Yran Chang, M.D.

Chief Strategy Officer,

Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan

Kuang-Kuo Chen, M.D.

Professor,

Department of Urology, Cheng Hsin Hospital, Taipei, Taiwan

Jun Chen, M.D.

Professor, Dean,

West Garden Hospital West Garden District, Taipei, Taiwan

Vincent H. S. Chiang, M.D. Ph.D.

Professor,

Graduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City, Taiwan

Chun Hsiung Huang, M.D., Ph.D.

Honorary Professor,

Kaohsiung Medical University, Kaohsiung, Taiwan

Jong-Khing Huang, M.D.

Consultant,

Kaohsiun Veterans General Hospital, Kaohsiung, Taiwan

Thomas I. S. Hwang, M.D.

Professor, Chief,

Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Hann-Chorng Kuo, M.D.

Chief,

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,

Tzu Chi University, Hualien, Taiwan

Ming-Kuen Lai, M.D.

Attending Physician,

Division of Urology, Department of Surgery, Luo-Dong Saint Mary's Hospital, Yilan, Taiwan

Alex T.L. Lin, M.D., Ph.D.

Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan

Yeong-Shiau Pu, M.D., Ph.D. EMBA

Department of Urology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan

Guang-Huan Sun, M.D.

Professor,

Division of Urology, Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan

Wen-Jeng Wu, M.D., Ph.D.

Vice-superintendent,

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Stephen Shei-Dei Yang, M.D., Ph.D.

Professor, Vice Superintendent,

Department of Urology, Taipei Tzu Chi Hospital, New Taipei City, Taiwan

Dah-Shyong Yu, M.D., Ph.D.

Professor and Visiting Surgeon,

Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Hong-Jeng Yu

Professor,

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan



## Editorial

# Adiponectin and Proto-oncogene MYC in Prostate Cancer: How Far Are We with the Evidence?

The GLOBOCAN data 2018 shows that prostate cancer (PCa) is the most common malignancy among males, and represents the 5<sup>th</sup> leading death of cancer in men.<sup>[1]</sup> Although some risk factors have been identified, the clear etiology of this disease remains unclear.

Obesity, adiposity, and high body mass index have found to be associated with PCa and its biochemical recurrence, but the underlying mechanism remains unknown.<sup>[2,3]</sup> Adipocyte is a secretory organ that produces several hormones, cytokines, and growth factors called adipokines. Among these adipokines, adiponectin (APN) has been robustly studied and found to be associated with PCa.<sup>[4-6]</sup>

Studies on the association between APN and PCa have resulted in contradictory results. Some studies have proven its association, whereas others failed.<sup>[7,8]</sup> Among those who succeeded, some confirmed positive correlations, whereas others have negatively reported.<sup>[9-11]</sup> One of the rational explanations behind these conflicted evidence was proven to be correlated with the genetic polymorphisms, leading to various risks associated with PCa. The AdipoQ rs2241766 allele and AdipoR1 rs10920531 were associated with higher risk of PCa; meanwhile, the AdipoR1 rs2232853 variant was associated with a lower risk.<sup>[12]</sup>

The current predominance of evidence has shown an inverse correlation between APN and prostate malignancy. Therefore, an alteration of APN may potentially be used as a marker for early detection, to predict metastasis and a guidance for targeted therapy.<sup>[13]</sup>

Moreover, the proto-oncogene MYC is a family of regulator genes that code for transcription factors. It consists of c-MYC (also refers to MYC), I-MYC, and n-MYC. The proto-oncogene MYC has been thought to be responsible for the regulation of cellular metabolism, proliferation, and apoptosis. Its amplification occurs in 10%–30% of localized PCa, and more than 50% of advanced tumors have been linked to poorer prognosis.<sup>[14-17]</sup>

Studies on MYC as a biomarker for PCa have been intensively conducted, mainly using immunohistochemistry technique to

identify the expression of MYC and correlate them with the clinicopathological aspects of PCa. Various MYC antibodies, cellular staining localization (nucleus or cytoplasmic), and scoring systems have been adopted, leading to various conclusions related to PCa.<sup>[18]</sup> A study by Pettersson *et al.* (2018) on MYC at the protein and mRNA level has shown that neither MYC protein overexpression nor MYC mRNA overexpression is a strong prognostic marker following radical prostatectomy.<sup>[17]</sup> Some studies have reported a positive association between MYC expression and clinicopathological factors of PCa, whereas others have negatively reported or even proven to be unassociated.<sup>[19-21]</sup> The short half-life of MYC protein, the different role between MYC protein and MYC gene amplification, and the possibility of different gene amplification rather than 8q/8q24 are all the possible explanations to these contradictory evidence.

Looking back to the current evidence of APN and proto-oncogene MYC in their relation to the clinicopathological factors of PCa, further studies need to be conducted focusing on the exact association, prior to its application in the clinical setting.

**Lukman Hakim\***

Department of Urology, Faculty of Medicine at Airlangga University, Dr. Soetomo Hospital, Surabaya, Indonesia

**Address for correspondence:**

Dr. Lukman Hakim,  
Department of Urology, Faculty of Medicine at Airlangga University/  
Dr. Soetomo Hospital, Mayjend Moestopo 6-8, Surabaya 60286, Indonesia.  
E-mail: [lukman-h@fk.unair.ac.id](mailto:lukman-h@fk.unair.ac.id)

22 September 2019

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
2. Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q. Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: A dose-response meta-analysis of 29,464 patients. *PLoS One* 2014;9:e106677.
3. Bai PD, Hu MB, Xu H, Zhu WH, Hu JM, Yang T, *et al.* Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: A retrospective cohort

- study and meta-analysis. *World J Surg Oncol* 2015;13:311.
4. Liao Q, Long C, Deng Z, Bi X, Hu J. The role of circulating adiponectin in prostate cancer: A meta-analysis. *Int J Biol Markers* 2015;30:e22-31.
  5. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. *Endocr Rev* 2011;32:550-70.
  6. Freedland SJ, Williams CD, Masko EM. Adiponectin and prostate cancer mortality: To be or not to be skinny? *Clin Chem* 2010;56:1-3.
  7. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, *et al.* Obesity, adipokines, and prostate cancer in a prospective population-based study. *Cancer Epidemiol Biomarkers Prev* 2006;15:1331-5.
  8. Wei T, Ye P, Peng X, Wu LL, Yu GY. Circulating adiponectin levels in various malignancies: An updated meta-analysis of 107 studies. *Oncotarget* 2016;7:48671-91.
  9. Ikeda A, Nakagawa T, Kawai K, Onozawa M, Hayashi T, Matsushita Y, *et al.* Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer. *Prostate Int* 2015;3:87-92.
  10. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, *et al.* A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. *Clin Chem* 2010;56:34-43.
  11. Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, *et al.* Tumor expression of adiponectin receptor 2 and lethal prostate cancer. *Carcinogenesis* 2015;36:639-47.
  12. Hu MB, Xu H, Hu JM, Zhu WH, Yang T, Jiang HW, *et al.* Genetic polymorphisms in leptin, adiponectin and their receptors affect risk and aggressiveness of prostate cancer: Evidence from a meta-analysis and pooled-review. *Oncotarget* 2016;7:81049-61.
  13. Tumminia A, Vinciguerra F, Parisi M, Graziano M, Sciacca L, Baratta R, *et al.* Adipose tissue, obesity and adiponectin: Role in endocrine cancer risk. *Int J Mol Sci* 2019;20. pii: E2863.
  14. Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, *et al.* Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. *Cancer* 2012;118:4053-62.
  15. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, *et al.* Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. *Mod Pathol* 2002;15:35-44.
  16. Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJ, Andersson KE, Hedlund P. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: Influence of *in vivo* gene therapy of PKG1alpha. *BJU Int* 2007;99:1488-94.
  17. Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, *et al.* MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2018;27:201-7.
  18. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. *Genes Cancer* 2010;1:617-28.
  19. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, *et al.* 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. *Hum Pathol* 2013;44:1617-23.
  20. Prowatke I, Devens F, Benner A, Gröne EF, Mertens D, Gröne HJ, *et al.* Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. *Br J Cancer* 2007;96:82-8.
  21. Gurel B, Iwata T, Koh C, Jenkins RB, Lan F, Van Dang C, *et al.* Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. *Mod Pathol* 2008;21:1156-67.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
<b>Quick Response Code:</b> 	<b>Website:</b> <a href="http://www.e-urol-sci.com">www.e-urol-sci.com</a>
	<b>DOI:</b> 10.4103/UROS.UROS_69_19

**How to cite this article:** Hakim L. Adiponectin and proto-oncogene MYC in prostate cancer: How far are we with the evidence? *Urol Sci* 2019;30:197-8.